Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07112196 · ClinicalTrials.gov registry record · Phase 2
Visugromab in Cachexia International Trial
A Phase 2 study of Cancer-associated Cachexia, sponsored by CatalYm.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 518
- Enrollment target
- 1
- Study location
NCT07112196 is a Phase 2 study of Cancer-associated Cachexia that is actively recruiting participants, run by CatalYm. The registered enrollment target is 518 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07112196, a Phase 2 study of Cancer-associated Cachexia, is actively recruiting participants, sponsored by CatalYm.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 518 participants
- Enrollment target
- 1
- Study location
Study Summary
A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better appetite? * Does visugromab help participants move more and better? * What medical problems do participants have when taking visugromab? Researchers will compare visugromab to a placebo (a look-alike substance that contains no drug). Participants will visit the hospital or clinic once every 4 weeks to receive visugromab or placebo via a drip into a vein and to undergo checkups and tests.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Visugromab (CTL-002)
Study Locations (1)
Florida
- Mid Florida Hematology and Oncology Centers - Orange City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 518 participants |
| Start Date | 2026-01 |
| Est. Completion | 2030-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07112196
The ClinicalTrials.gov registry entry for NCT07112196 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 518 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is CatalYm, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Cancer-associated Cachexia appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT07112196 reports 1 study location spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT07112196 about?
NCT07112196 is a clinical study titled "Visugromab in Cachexia International Trial". A study of how well and safely a new drug called visugromab works in people with certain kinds of cancer (including lung and bowel cancer) and unintended weight loss known as cachexia. The main questions it aims to answer are: * Does visugromab help participants put weight back on and have a better...
What is the current status of trial NCT07112196?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 518 participants. The study started on 2026-01. Estimated completion is 2030-12.
What conditions does trial NCT07112196 study?
This clinical trial studies the following conditions: Cancer-associated Cachexia.
What interventions are being tested in trial NCT07112196?
The interventions under investigation include: Placebo (DRUG), Visugromab (CTL-002) (DRUG).
Who is sponsoring clinical trial NCT07112196?
This trial is sponsored by CatalYm, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07112196 being conducted?
This trial has 1 study location across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.